The potential indirect effect of conjugate pneumococcal vaccines

Research output: Contribution to journalArticle

Abstract

Pneumococcal conjugate vaccines are highly effective in preventing invasive disease in infants and young children, with favorable safety and immunogenicity profiles. These pediatric vaccines have also shown efficacy in reducing cases of non-invasive disease (i.e. otitis media, pneumonia). Recently, pneumococcal conjugate vaccines have demonstrated additional protective qualities that may enhance their use worldwide. For example, they can reduce nasopharyngeal acquisition of vaccine-specific serotypes of Streptococcus pneumoniae, which may in turn reduce the incidence of pneumococcal disease among non-vaccinated individuals; this is termed indirect or herd immunity. Although the emergence of antibiotic-resistant strains has complicated disease management, pneumococcal conjugate vaccines have been shown to protect against pneumococcal disease caused by such strains because most antibiotic-resistant strains are of the serotypes included in these vaccines. Thus, widespread use of these conjugate vaccines may prevent disease by providing both direct and indirect immunity, and may reduce the use of antibiotics and the development of antibiotic resistance worldwide.

Original languageEnglish (US)
Pages (from-to)1815-1825
Number of pages11
JournalVaccine
Volume21
Issue number17-18
DOIs
StatePublished - May 16 2003

Fingerprint

Conjugate Vaccines
Pneumococcal Vaccines
vaccines
Vaccines
Anti-Bacterial Agents
antibiotics
Herd Immunity
serotypes
Otitis Media
Microbial Drug Resistance
Disease Management
Streptococcus pneumoniae
otitis media
Immunity
Pneumonia
Pediatrics
antibiotic resistance
disease incidence
pneumonia
Safety

Keywords

  • Antibiotics
  • Drug resistance
  • Immunity
  • Pneumococcal conjugate vaccines
  • Streptococcus pneumoniae

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

The potential indirect effect of conjugate pneumococcal vaccines. / O'Brien, Katherine L; Dagan, Ron.

In: Vaccine, Vol. 21, No. 17-18, 16.05.2003, p. 1815-1825.

Research output: Contribution to journalArticle

O'Brien, Katherine L ; Dagan, Ron. / The potential indirect effect of conjugate pneumococcal vaccines. In: Vaccine. 2003 ; Vol. 21, No. 17-18. pp. 1815-1825.
@article{b173cd41c7fe434084e85b2ecfcdaf4b,
title = "The potential indirect effect of conjugate pneumococcal vaccines",
abstract = "Pneumococcal conjugate vaccines are highly effective in preventing invasive disease in infants and young children, with favorable safety and immunogenicity profiles. These pediatric vaccines have also shown efficacy in reducing cases of non-invasive disease (i.e. otitis media, pneumonia). Recently, pneumococcal conjugate vaccines have demonstrated additional protective qualities that may enhance their use worldwide. For example, they can reduce nasopharyngeal acquisition of vaccine-specific serotypes of Streptococcus pneumoniae, which may in turn reduce the incidence of pneumococcal disease among non-vaccinated individuals; this is termed indirect or herd immunity. Although the emergence of antibiotic-resistant strains has complicated disease management, pneumococcal conjugate vaccines have been shown to protect against pneumococcal disease caused by such strains because most antibiotic-resistant strains are of the serotypes included in these vaccines. Thus, widespread use of these conjugate vaccines may prevent disease by providing both direct and indirect immunity, and may reduce the use of antibiotics and the development of antibiotic resistance worldwide.",
keywords = "Antibiotics, Drug resistance, Immunity, Pneumococcal conjugate vaccines, Streptococcus pneumoniae",
author = "O'Brien, {Katherine L} and Ron Dagan",
year = "2003",
month = "5",
day = "16",
doi = "10.1016/S0264-410X(02)00807-1",
language = "English (US)",
volume = "21",
pages = "1815--1825",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "17-18",

}

TY - JOUR

T1 - The potential indirect effect of conjugate pneumococcal vaccines

AU - O'Brien, Katherine L

AU - Dagan, Ron

PY - 2003/5/16

Y1 - 2003/5/16

N2 - Pneumococcal conjugate vaccines are highly effective in preventing invasive disease in infants and young children, with favorable safety and immunogenicity profiles. These pediatric vaccines have also shown efficacy in reducing cases of non-invasive disease (i.e. otitis media, pneumonia). Recently, pneumococcal conjugate vaccines have demonstrated additional protective qualities that may enhance their use worldwide. For example, they can reduce nasopharyngeal acquisition of vaccine-specific serotypes of Streptococcus pneumoniae, which may in turn reduce the incidence of pneumococcal disease among non-vaccinated individuals; this is termed indirect or herd immunity. Although the emergence of antibiotic-resistant strains has complicated disease management, pneumococcal conjugate vaccines have been shown to protect against pneumococcal disease caused by such strains because most antibiotic-resistant strains are of the serotypes included in these vaccines. Thus, widespread use of these conjugate vaccines may prevent disease by providing both direct and indirect immunity, and may reduce the use of antibiotics and the development of antibiotic resistance worldwide.

AB - Pneumococcal conjugate vaccines are highly effective in preventing invasive disease in infants and young children, with favorable safety and immunogenicity profiles. These pediatric vaccines have also shown efficacy in reducing cases of non-invasive disease (i.e. otitis media, pneumonia). Recently, pneumococcal conjugate vaccines have demonstrated additional protective qualities that may enhance their use worldwide. For example, they can reduce nasopharyngeal acquisition of vaccine-specific serotypes of Streptococcus pneumoniae, which may in turn reduce the incidence of pneumococcal disease among non-vaccinated individuals; this is termed indirect or herd immunity. Although the emergence of antibiotic-resistant strains has complicated disease management, pneumococcal conjugate vaccines have been shown to protect against pneumococcal disease caused by such strains because most antibiotic-resistant strains are of the serotypes included in these vaccines. Thus, widespread use of these conjugate vaccines may prevent disease by providing both direct and indirect immunity, and may reduce the use of antibiotics and the development of antibiotic resistance worldwide.

KW - Antibiotics

KW - Drug resistance

KW - Immunity

KW - Pneumococcal conjugate vaccines

KW - Streptococcus pneumoniae

UR - http://www.scopus.com/inward/record.url?scp=0037449068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037449068&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(02)00807-1

DO - 10.1016/S0264-410X(02)00807-1

M3 - Article

C2 - 12706665

AN - SCOPUS:0037449068

VL - 21

SP - 1815

EP - 1825

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 17-18

ER -